Triazole Appending Agent (TAAG): A New Synthon for Preparing Iodine-Based Molecular Imaging and Radiotherapy Agents Academic Article uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • A new prosthetic group referred to as the triazole appending agent (TAAG) was developed as a means to prepare targeted radioiodine-based molecular imaging and therapy agents. Tributyltin-TAAG and the fluorous analogue were synthesized in high yield using simple click chemistry and the products labeled in greater than 95% RCY with (123)I. A TAAG derivative of an inhibitor of prostate-specific membrane antigen was prepared and radiolabeled with (123)I in 85% yield where biodistribution studies in LNCap prostate cancer tumor models showed rapid clearance of the agent from nontarget tissues and tumor accumulation of 20% injected dose g(-1) at 1 h. The results presented demonstrate that the TAAG group promotes minimal nonspecific binding and that labeled conjugates can achieve high tumor uptake and exquisite target-to-nontarget ratios.


  • Darwish, Alla
  • Blacker, Megan
  • Janzen, Nancy
  • Rathmann, Stephanie M
  • Czorny, Shannon
  • Hillier, Shawn M
  • Joyal, John L
  • Babich, John W
  • Valliant, John F

publication date

  • April 12, 2012